Forskolin: another natural compound goes on my list of myeloma killers

Yesterday I came across a 2015 study that really caught my attention. A group of Norwegian researchers has discovered that the combination of dexamethasone with a natural compound called forskolin kills multiple myeloma cells. They tested forskolin with other conventional myeloma drugs, too: bortezomib (Velcade), cyclophosphamide, doxorubicin, and melphalan. And by itself. Results in a nutshell: dead myeloma cells.    Excerpt from the abstract: “Our findings support a potential role of forskolin in combination with current conventional agents in the treatment of MM.” The researchers believe that forskolin might be able “to diminish treatment-associated side effects,” which of course would have a huge impact, obviously a very positive one!!!, on a patient’s quality of life…indeed, on the QOL of countless patients… Of course, this is all theoretical, since the researchers used MM cell lines, not actual human beings. I checked the clinical trial website where I found only a few trials testing forskolin for various conditions, mostly eye, weight loss, and lung-related (interesting aside: there were a couple of cystic fibrosis studies there, too). No myeloma clinical trials. Are you surprised? I wasn’t. I mean, we know WHO finances almost all the clinical trials…and the ghastly rich and powerful pharmaceutical companies aren’t going to be interested in an affordable natural compound, are they? No pr...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll forskolin myeloma Source Type: blogs

Related Links:

This study estimated healthcare costs and utilisation for patients with AR and asthma. Mean annual outpatient visits, pharmaceutical costs and inpatient hospitalisations were calculated for 2010 and 2014, with pharmaceutical and inpatient costs stratified by AIT use. AR and asthma patients had a 35% higher mean number of physician visits and up to 90% higher mean pharmaceutical costs compared to controls. The cost of pharmaceuticals and inpatient hospitalisations were 54% lower in those prescribed AIT. Further research is recommended to understand the reasons for these cost differences. PMID: 31818082 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
We report a case of serum sickness-like reaction in a patient treated with omalizumab for chronic idiopathic urticaria/angioedema. An adult female experienced episodic urticaria/angioedema without repeatable trigger, ultimately receiving diagnosis of chronic idiopathic urticaria/angioedema. After initial treatment, attempts with escalating cetirizine and montelukast doses were unsuccessful due to sedation; she began treatment with subcutaneous omalizumab 150 mg monthly. Urticaria frequency partially improved after two injections; therefore, the dose was increased to 300 mg after four treatments. Several days afte...
Source: Military Medicine - Category: International Medicine & Public Health Tags: Mil Med Source Type: research
[This Day] Abuja -Over 5,000 persons have benefited from diabetes, hypertension, cervical and breast cancer free screening, which was facilitated by MITEDA Wellness Initiative, a nongovernmental organisation and in collaboration with the Lagos State government.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Authors: Chen LC, Zeng GS, Wu LL, Zi M, Fang ZK, Fan HZ, Yu HP Abstract Objective: To evaluate the diagnostic value of fractional exhaled nitric oxide (FeNO) and maximum mid-expiratory flow (MMEF) for differentiating cough variant asthma (CVA) from chronic cough in patients with or without allergic rhinitis.Methods: In total, 328 patients with chronic cough who underwent spirometry and FeNO testing were consecutively included in the retrospective analysis. Patients were divided into the CVA (n = 125) or NCVA (n = 203) groups according to the diagnostic criteria of CVA. Receiver operating...
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
(Elsevier) High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a potentially fatal disease caused by obstruction of blood flow in the lungs. A new study in The American Journal of Pathology, published by Elsevier, sheds light on the pathology underlying PAH and shows that dofetilide, an FDA-approved KV11.1 channel blocker for the treatment of cardiac arrhythmias (brand name: Tikosyn), may be used for treatment of PAH.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 10 December 2019Source: The LancetAuthor(s): Maria-Victoria Mateos, Michele Cavo, Joan Blade, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki FujisakiSummaryBackgroundStandard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous stem-cell transplantation. At the primary analysis ...
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 10 December 2019Source: The LancetAuthor(s): Manisha Bhutani, Saad Z Usmani
Source: The Lancet - Category: General Medicine Source Type: research
ConclusionThe online server and web-interface are aimed at facilitating the health organizations and medical councils to monitor the antibiotic prescription and their consumption in real time. This will not only augment the existing policy-making regarding drug-resistance programs but also promote the collection and downstream exploratory analysis of huge amount of data to get a deeper insight into the epidemiology of tuberculosis and related diseases.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
Obesity is one of the most significant medical conditions in today's adult population, occurring at an estimated frequency of 35% with prevalence rates continuing to rise.1 In surgery, obesity has been shown to be an independent preoperative risk factor for unfavorable outcomes.2 This poses a challenge to plastic surgeons, especially since many of these procedures are aimed to treat the sequela of obesity and massive weight loss.
Source: Journal of Plastic, Reconstructive and Aesthetic Surgery - Category: Cosmetic Surgery Authors: Tags: Correspondence and Communications Source Type: research
Publication date: Available online 11 December 2019Source: American Heart JournalAuthor(s): Geoffrey Lau, Maria Koh, Peter A. Kavsak, Michael J. Schull, David W.J. Armstrong, Jacob A. Udell, Peter C. Austin, Xuesong Wang, Dennis T. KoABSTRACTBackgroundHigh-sensitivity cardiac troponin (hs-cTn) assays enhance detection of lower circulating troponin concentrations, but the impact on outcomes in clinical practice is unclear. Our objective was to compare outcomes of chest pain patients discharged from emergency departments (EDs) using hs-cTn and conventional troponin (cTn) assays.MethodsWe conducted an observational study of c...
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Asthma | Beta-Blockers | Blogging | Cardiology | Clinical Trials | Coumadin | Cystic Fibrosis | Dexamethasone | Gastroenterology | Heart | Hypertension | India Health | Men | Myeloma | Norway Health | Study | Toxicology | Urology & Nephrology | Velcade | Warfarin | Websites | Weight Loss